Market Cap 93.36M
Revenue (ttm) 33.03M
Net Income (ttm) -44.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -135.12%
Debt to Equity Ratio 0.00
Volume 358,400
Avg Vol 851,430
Day's Range N/A - N/A
Shares Out 107.12M
Stochastic %K 53%
Beta 1.37
Analysts Strong Sell
Price Target $4.67

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applicatio...

Industry: Medical Devices
Sector: Healthcare
Phone: 301 944 1700
Address:
9713 Key West Avenue, Suite 400, Rockville, United States
Mindegap
Mindegap May. 1 at 5:50 PM
$MXCT Hmmm...looks like slow and steady accumulation. They work with: $CRSP $ALLO $CRBU and others.
0 · Reply
StockConsultant
StockConsultant Apr. 28 at 12:15 PM
$MXCT MaxCyte stock, watch for a bottom breakout at https://stockconsultant.com/?MXCT
0 · Reply
pleasemoney
pleasemoney Apr. 22 at 2:05 PM
0 · Reply
Mindegap
Mindegap Apr. 20 at 7:50 PM
If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 11:22 PM
$MXCT RSI: 70.90, MACD: 0.0120 Vol: 0.06, MA20: 0.76, MA50: 0.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 8:15 PM
$MXCT Share Price: $0.85 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.11 – $0.14 Target Zone: $0.19 – $0.23 Potential Upside: 55% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
burbs88
burbs88 Apr. 15 at 1:27 PM
$MXCT I'm going to go ahead and take a nibble here.
0 · Reply
Mindegap
Mindegap Apr. 14 at 2:19 PM
$MXCT Can help all MaxCyte customers. Today, the FDA issued a draft guidance that when finalized, will provide recommendations for standardized methods for sponsors developing human gene therapy products that incorporate genome editing technologies. https://fda.gov/news-events/press-announcements/fda-issues-draft-guidance-genome-editing-safety-standards-advance-gene-therapy-development
0 · Reply
Mindegap
Mindegap Apr. 13 at 1:23 PM
$MXCT $ALLO had great results this morning. They use $MXCT tech.
0 · Reply
Hertha
Hertha Apr. 13 at 1:07 AM
$MXCT The platform is already embedded at the regulated cell-engineering layer through clinical and commercial licensing, FDA Master File, and documented methodology-switching burden, across 31 active SPL partnerships with one commercial and 13 clinical programs.
0 · Reply
Latest News on MXCT
MaxCyte price target lowered to $5 from $7 at Craig-Hallum

2026-03-25T13:41:55.000Z - 6 weeks ago

MaxCyte price target lowered to $5 from $7 at Craig-Hallum


MaxCyte Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 6 weeks ago

MaxCyte Earnings Call Transcript: Q4 2025


MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M

2026-03-24T20:22:34.000Z - 6 weeks ago

MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M


MaxCyte reports Q4 EPS (9c), consensus (8c)

2026-03-24T20:16:47.000Z - 6 weeks ago

MaxCyte reports Q4 EPS (9c), consensus (8c)


MaxCyte appoints Parmeet Ahuja as CFO

2026-03-23T12:20:40.000Z - 6 weeks ago

MaxCyte appoints Parmeet Ahuja as CFO

A


MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Mar 23, 2026, 8:05 AM EDT - 6 weeks ago

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer


MaxCyte announced the launch of ExPERT DTx

2026-02-24T13:37:10.000Z - 2 months ago

MaxCyte announced the launch of ExPERT DTx


MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M

2026-01-12T13:15:35.000Z - 4 months ago

MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M


MaxCyte management to meet with Craig-Hallum

2025-12-02T18:55:28.000Z - 5 months ago

MaxCyte management to meet with Craig-Hallum


MaxCyte Transcript: Stephens Annual Investment Conference

Nov 19, 2025, 9:00 AM EST - 6 months ago

MaxCyte Transcript: Stephens Annual Investment Conference


MaxCyte CFO Douglas Swirsky to transition out of role

2025-11-12T22:20:36.000Z - 6 months ago

MaxCyte CFO Douglas Swirsky to transition out of role


MaxCyte reports Q3 EPS (12c), consensus (9c)

2025-11-12T21:55:21.000Z - 6 months ago

MaxCyte reports Q3 EPS (12c), consensus (9c)


MaxCyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 6 months ago

MaxCyte Earnings Call Transcript: Q3 2025


MaxCyte Announces Planned CFO Transition in 2026

Nov 12, 2025, 4:08 PM EST - 6 months ago

MaxCyte Announces Planned CFO Transition in 2026


MaxCyte reiterates 2025 revenue guidance

2025-11-05T13:16:57.000Z - 6 months ago

MaxCyte reiterates 2025 revenue guidance


MaxCyte reports preliminary Q3 revenue $6.8M, consensus $8.37M

2025-11-05T13:10:23.000Z - 6 months ago

MaxCyte reports preliminary Q3 revenue $6.8M, consensus $8.37M


MaxCyte enters platform license agreement with Moonlight Bio

2025-10-06T12:36:36.000Z - 7 months ago

MaxCyte enters platform license agreement with Moonlight Bio


MaxCyte downgraded to Neutral from Buy at BTIG

2025-08-11T10:10:09.000Z - 9 months ago

MaxCyte downgraded to Neutral from Buy at BTIG


MaxCyte reports Q2 EPS (12c), consensus (10c)

2025-08-06T21:11:47.000Z - 9 months ago

MaxCyte reports Q2 EPS (12c), consensus (10c)


MaxCyte sees FY25 core revenue flat to down 10%

2025-08-06T21:11:25.000Z - 9 months ago

MaxCyte sees FY25 core revenue flat to down 10%


MaxCyte Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

MaxCyte Earnings Call Transcript: Q2 2025


MaxCyte signs platform license agreement with Adicet Bio

2025-08-04T12:21:57.000Z - 9 months ago

MaxCyte signs platform license agreement with Adicet Bio


MaxCyte Signs Platform License Agreement with Adicet Bio

Aug 4, 2025, 8:05 AM EDT - 9 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio


MaxCyte initiated with an Overweight at Stephens

2025-07-21T22:40:09.000Z - 10 months ago

MaxCyte initiated with an Overweight at Stephens


MaxCyte Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

MaxCyte Earnings Call Transcript: Q1 2025


MaxCyte Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

MaxCyte Earnings Call Transcript: Q4 2024


MaxCyte Announces Retirement of Board Member Art Mandell

Dec 23, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Retirement of Board Member Art Mandell


MaxCyte Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 10:55 AM EST - 1 year ago

MaxCyte Transcript: Stifel 2024 Healthcare Conference


MaxCyte Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

MaxCyte Earnings Call Transcript: Q3 2024


MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences


MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors


MaxCyte Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

MaxCyte Earnings Call Transcript: Q2 2024


MaxCyte Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

MaxCyte Earnings Call Transcript: Q1 2024


MaxCyte Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

MaxCyte Earnings Call Transcript: Q4 2023


Mindegap
Mindegap May. 1 at 5:50 PM
$MXCT Hmmm...looks like slow and steady accumulation. They work with: $CRSP $ALLO $CRBU and others.
0 · Reply
StockConsultant
StockConsultant Apr. 28 at 12:15 PM
$MXCT MaxCyte stock, watch for a bottom breakout at https://stockconsultant.com/?MXCT
0 · Reply
pleasemoney
pleasemoney Apr. 22 at 2:05 PM
0 · Reply
Mindegap
Mindegap Apr. 20 at 7:50 PM
If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 11:22 PM
$MXCT RSI: 70.90, MACD: 0.0120 Vol: 0.06, MA20: 0.76, MA50: 0.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 8:15 PM
$MXCT Share Price: $0.85 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.11 – $0.14 Target Zone: $0.19 – $0.23 Potential Upside: 55% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
burbs88
burbs88 Apr. 15 at 1:27 PM
$MXCT I'm going to go ahead and take a nibble here.
0 · Reply
Mindegap
Mindegap Apr. 14 at 2:19 PM
$MXCT Can help all MaxCyte customers. Today, the FDA issued a draft guidance that when finalized, will provide recommendations for standardized methods for sponsors developing human gene therapy products that incorporate genome editing technologies. https://fda.gov/news-events/press-announcements/fda-issues-draft-guidance-genome-editing-safety-standards-advance-gene-therapy-development
0 · Reply
Mindegap
Mindegap Apr. 13 at 1:23 PM
$MXCT $ALLO had great results this morning. They use $MXCT tech.
0 · Reply
Hertha
Hertha Apr. 13 at 1:07 AM
$MXCT The platform is already embedded at the regulated cell-engineering layer through clinical and commercial licensing, FDA Master File, and documented methodology-switching burden, across 31 active SPL partnerships with one commercial and 13 clinical programs.
0 · Reply
noccers
noccers Apr. 10 at 6:22 AM
$MXCT Hammer time.
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 9 at 1:27 PM
🌅 Watchlist part 3 ✅ $ALBT .50 support, if above .70, has potential to .80/1.00 ✅ $UCAR 2.20 support, if above 2.60, has potential to 2.80/3.30 ✅ $VEEE .20 support, if above .30, has potential to .40/.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 9 at 5:04 AM
🌅 Watchlist part 2 ✅ $ARAI .70 support, if above 1, has potential to 1.20/1.30 ✅ $UCAR 3.0 support, if above 3.50, has potential to 3.80/3.90 ✅ $VEEE .30 support, if above .40, has potential to .50/.55 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN, not GREED
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 8 at 1:26 PM
🌅 Watchlist part 3 ✅ $IRIX 1.05 support, if above 1.30, have potential to 1.50/.70 ✅ $WGRX .10 support, if above .20, have potential to .30/.40 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D.
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 8 at 3:35 AM
🌅 Watchlist part 3 ✅ $QNCX .20 support, if above .30, have potential to .40/.60 ✅ $NXTS 1/7 RS, new price ~4.18 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳ $MXCT, $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN, not GREED
0 · Reply
Mylov
Mylov Apr. 7 at 4:43 PM
$MXCT lets go up
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 7 at 2:58 AM
🌅 Watchlist part 2 ✅ $SILO .50 support, if above .60, have potential to .70/.75 ✅ $BGDE 3 support, if above 3.65, have potential to 3.80/4 ✅ $TBH .50 support, if above .65, have potential to .70/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN, not GREED
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 6 at 1:30 PM
🌅 Watchlist PART 2 ✅ $BTBD low 2 support, if above 2.30, have potential to 2.50/.80 ✅ $SKYQ 4.50 support, if above 5, have potential to 5.40/.70 ✅ $COCP 1.30 support, if above 1.60, have potential to 1.80/2.20 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D.
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Apr. 6 at 3:02 AM
🌅 Watchlist part 2 ✅ $GV .30 support, if above .45, has potential to .50/.60 ✅ $SKYQ , if above 5, has potential to 5.40/5.70 ✅ $COCP 1.30 support, if above 1.60, has potential to 1.80/2.20 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN not GREED
0 · Reply
Ziana_u
Ziana_u Mar. 27 at 7:45 PM
$MXCT ready 🔥🔥
0 · Reply
Ray89c
Ray89c Mar. 25 at 7:25 PM
$MXCT why analyst rating pricing of 5 lol
0 · Reply
nomen
nomen Mar. 25 at 12:25 AM
$MXCT Haha first question on the call is spot on. Man I just don’t know if this company is run well enough to survive the Trump admin. Thinking it goes to 50-60 million cap and probably gets taken out
3 · Reply